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The apicomplexan parasite Toxoplasma gondii is a leading opportunistic pathogen associated with AIDS and
congenital birth defects. Due to the need for identifying new parasite-specific treatments, the possibility of
targeting sphingolipid biosynthesis in the parasite was investigated. Aureobasidin A, an inhibitor of the enzyme
synthesizing the sphingolipid inositol phosphorylceramide, which is present in fungi, plants, and some pro-
tozoa but absent in mammalian cells, was found to block in vitro T. gondii replication without affecting host cell
metabolism. Aureobasidin A treatment did not induce tachyzoite to bradyzoite stage conversion in T. gondii but
resulted in a loss of intracellular structures and vacuolization within the parasite. In addition, aureobasidin
A inhibited sphingolipid synthesis in T. gondii. Sphingolipid biosynthetic pathways may therefore be considered
targets for the development of anti-T. gondii agents.
The apicomplexan parasite Toxoplasma gondii is an impor-
tant agent of human disease. The broad host range of the
parasite, including virtually all warm-blooded animals (10),
and its high infection rates, which in humans average 10 to
30% but can reach 90% (6), contribute to the widespread
distribution of T. gondii. In immunocompetent individuals, T.
gondii induces chronic, normally asymptomatic infections fol-
lowing its conversion from the invasive tachyzoite stage to the
slowly replicating bradyzoite stage. Bradyzoites reside in qui-
escent tissue cysts in the brain of the host organism and gen-
erally persist in this form throughout the host life span (10).
However, serious cases of toxoplasmosis most commonly occur
either following congenital transmission of the parasite to the
fetus (often resulting in abortion or neurological disorders and
blindness) or following immunosuppression in previously
asymptomatic adults (commonly associated with organ trans-
plantation or diseases such as AIDS), resulting in toxoplasmic
encephalitis with mortality rates exceeding 30% (40). With the
significantly increased number of immunocompromised indi-
viduals, T. gondii is now recognized as one of the most common
opportunistic parasitic infections (8).
Despite efforts to develop effective anti-T. gondii vaccines,
chemotherapy remains the only treatment for T. gondii infec-
tions. Drugs affecting nucleotide metabolism, such as sulfadi-
azine and pyrimethamine, are among the most effective ther-
apies to date (26). However, toxicity, side effects, and the
development of resistance to currently available compounds
(1) highlight the need to improve our understanding of T.
gondii biology in order to identify parasite-specific drug targets.
In a search for a key biosynthetic pathway that is present in
T. gondii but absent from mammalian cells, we focused on
sphingolipid biosynthesis.
Sphingolipids are ubiquitous components of plasma mem-
branes. Their biosynthetic pathways are similar in all eukary-
otic cells up to the formation of ceramide. At this point, the
addition of the polar head group forms a branch in the path-
way, separating animals on one side from fungi, plants, and
kinetoplastid parasites on the other (Fig. 1) (21). The end
points of sphingolipid synthesis in fungi are inositol phospho-
rylceramide (IPC) and its derivatives (25). For these organ-
isms, the enzyme that catalyzes the formation of IPC, IPC
synthase, is well characterized and plays a pivotal role in the
regulation of intracellular levels of sphingolipids and ceramide
(21). Moreover, IPC synthase is an essential enzyme in fungi,
as its inhibition causes arrest in the cell cycle progression at G1,
followed by a loss of viability and alterations in the cytoskele-
ton (7, 11, 15, 16, 34). The antibiotic aureobasidin A is a potent
inhibitor of IPC synthase, causing lethality in a broad range of
pathogenic fungi without affecting the mammalian synthesis of
sphingolipids (11, 35).
In kinetoplastid parasites, such as Leishmania and Trypano-
soma, IPC has been shown to be a major component of the
sphingolipid pool (25, 29). However, in T. gondii, which is
known to synthesize mammal-like sphingolipids, such as sphin-
gomyelin (2), neither the presence of IPC nor the effect of
aureobasidin A has yet been characterized.
In the present study, we analyzed the effects of aureobasidin
A after in vitro treatment of T. gondii-infected cells with regard
to parasite survival, structural integrity, and lipid synthesis.
MATERIALS AND METHODS
Reagents and antibodies. Unless otherwise stated, all reagents were purchased
from Sigma. The antibiotic aureobasidin A was purchased from Takara Bio Inc.
(Shiga, Japan). Stock solutions of aureobasidin A were prepared at a concen-
tration of 2 mM in ethanol and freshly diluted to the concentrations required for
each experiment. All cell culture reagents were supplied by Gibco-BRL. Radio-
labeled reagents were purchased from Amersham Biosciences (Otelfingen, Swit-
zerland). The primary antibodies used in this study were a rabbit polyclonal
anti-T. gondii tachyzoite hyperimmune antiserum (13) and rabbit polyclonal
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anti-BAG5 antibodies (24). Fluorophore-conjugated secondary antibodies were
purchased from Molecular Probes (Eugene, Oreg.).
Parasite and tissue culture. T. gondii tachyzoites of the RH strain expressing
Escherichia coli -galactosidase (31) were used in this study. Parasites were
maintained by serial passages in human foreskin fibroblasts (HFF). HFF were
routinely cultured in RPMI 1640 medium supplemented with 10% fetal calf
serum, 2 mM glutamine, 50 U of penicillin/ml, and 50 g of streptomycin/ml at
37°C with 5% CO2 in tissue culture flasks. Cultures were trypsinized at least once
a week. Parasites were harvested from infected host cells after cell trypsinization,
repeatedly passed through a 25-gauge needle, and separated from host cell debris
by separation in Sephadex-G25 columns (Amersham Biosciences, Otelfingen,
Switzerland) as described previously (18). Prior to analyses, HFF were grown to
confluence on glass slides or 96-well plates.
Bradyzoite differentiation was induced in vitro by alkaline treatment as de-
scribed previously (33). Briefly, T. gondii tachyzoites were allowed to infect a host
cell monolayer for 2 h, and then the medium was replaced with RPMI 1640
containing 1-g/liter NaHCO3 and 50 mM Tricine that had been adjusted to pH
8.1 with NaOH. Cultures were incubated at 37°C in ambient CO2 for 4 days.
Immunofluorescence analysis. For analyses of intracellular T. gondii, infected
HFF monolayers grown on glass slides were washed in phosphate-buffered saline
(PBS), fixed in 4% paraformaldehyde in PBS, and permeabilized in 100% meth-
anol. After blocking in 1.5% bovine serum albumin in PBS, parasites were
visualized by staining with rabbit polyclonal sera against T. gondii tachyzoites at
a 1:1,000 dilution, followed by a fluorescein-conjugated anti-rabbit secondary
antibody. For analyses of parasite stage conversion to the bradyzoite form,
infected HFF monolayers were fixed in 4% paraformaldehyde and permeabilized
in 0.2% Triton X-100 in PBS, and parasites were detected by double fluorescence
staining after blocking in 1.5% bovine serum albumin. Parasites were first stained
with the bradyzoite-specific polyclonal antibody anti-BAG5 (1:250 dilution),
followed by a Cy3-conjugated anti-rabbit secondary antibody. Parasites were
then visualized by staining with rabbit polyclonal sera against T. gondii
tachyzoites (1:1,000 dilution), followed by a fluorescein-conjugated anti-rabbit
secondary antibody. Incubation with primary antibodies was performed for 30
min, followed by rinsing in PBS and incubation with the secondary antibodies for
an additional 30 min. Parasite and host cell nuclei were stained with 4,6-
diamidino-2-phenylindole (DAPI) for 2 min, rinsed in PBS, and mounted in
Fluoroguard antifade reagent (Bio-Rad, Hercules, Calif.). Samples were ana-
lyzed under a Zeiss Axioplan 2 fluorescence microscope (Jena, Germany).
Replication assay. HFF monolayers were infected for 2 h with T. gondii
tachyzoites (multiplicity of infection, 0.1). HFF monolayers were then washed to
remove extracellular parasites and were incubated with fresh medium containing
different concentrations of aureobasidin A, as indicated in the individual figure
legends. Parasite numbers were determined either after 24 h of drug treatment
by direct counting of parasites after immunolabeling, as described above, or after
48 h of drug treatment by colorimetric detection of the -galactosidase activity
expressed by the parasites, as described previously (27). Colorimetric analysis
was chosen to determine parasite numbers after 48 h of drug treatment because
at this time point the numbers of T. gondii tachyzoites contained in single
vacuoles do not allow precise visual counting of the parasites.
Host cell metabolic assay. The metabolic activity of host cells was tested by
using the AlamarBlue assay (BioSource International Inc., Camarillo, Calif.).
Briefly, HFF were grown to confluence in 96-well plates, treated for 48 h with the
test compounds indicated in the figure legends, and processed according to the
instructions provided by the manufacturer.
Transmission electron microscopy. HFF monolayers were grown in 75-cm2
flasks, infected with T. gondii tachyzoites at a multiplicity of infection of 1, and
treated with 10 g/ml of aureobasidin A or vehicle alone. After 24 h of drug
treatment, the cells were fixed in 100 mM sodium cacodylate, pH 7.2, containing
2.5% glutaraldehyde for 2 h at room temperature, followed by several washes in
100 mM sodium cacodylate, pH 7.2. Monolayers were scraped from the surfaces
of the tissue flasks by use of a rubber policeman. Postfixation in 2% OsO4 in
cacodylate buffer was carried out for 2 h at 4°C. Subsequently, specimens were
washed in water and then prestained with 1% uranyl acetate in water for 1 h at
4°C, followed by extensive washing. Specimens were then dehydrated in a graded
series of ethanol (50, 70, 90, and 100% [three times]) and were embedded in
Epon 820 resin. They were incubated at 40°C for 1 h, followed by a resin change,
and this procedure was repeated twice before the resin was allowed to infiltrate
for 2 days at room temperature. The resin was polymerized at 65°C over a period
of 24 h. Ultrathin sections were cut on a Reichert and Jung ultramicrotome and
were loaded onto 200- or 300-mesh copper grids (Plano GmbH, Marburg, Ger-
many). Staining with uranyl acetate and lead citrate was performed as previously
described (19). Finally, the grids were viewed with a Phillips 300 transmission
electron microscope operating at 60 kV.
Labeling and analysis of sphingolipids. For the labeling of lipids containing
inositol, T. gondii-infected HFF were incubated with myo-[3H]inositol (10 Ci/
ml) in the presence of 10 g/ml of aureobasidin A or vehicle alone for 24 h in
inositol-free RPMI 1640 medium (Sigma) supplemented with 10% calf serum.
Cells were then extensively washed in PBS, and intracellular parasites were
harvested from trypsinized host cells as described above. Lipids were extracted
twice from 108 parasites in chloroform-methanol-water (10:10:3) and dried un-
der a nitrogen stream, and aliquots were processed by mild alkaline hydrolysis to
deacylate the lipids. The samples were then butanol extracted before being dried
and applied to Silica Gel 60 HPTLC plates (20 by 20 cm; Merck, Darmstadt,
Germany). For total sphingolipid labeling, 108 purified parasites or 107 host cells
were incubated with [3H]palmitate (10 Ci/ml) in the presence of 10 g/ml of
aureobasidin A or vehicle alone for 7 h in RPMI 1640 medium supplemented
with 10% delipidated calf serum (Sigma). Lipids were extracted according to the
method of Bligh and Dyer (3), dried, and applied to Silica Gel 60 HPTLC plates.
Plates were developed in chloroform–methanol–0.25% KCl (55:45:10) (solvent
system A) for inositol-labeled lipid analysis or in chloroform–methanol–2 N
NH4OH (80:15:2) (solvent system B) for total sphingolipid analysis. Radiola-
beled spots were visualized by use of a tritium-sensitive screen (Perkin-Elmer,
Boston, Mass.) and were quantified in a Storm 840 phosphorimager using Im-
ageQuant software (Amersham, Otelfingen, Switzerland). Ten micrograms each
of ceramide (Avanti Polar, Alabama) and sphingomyelin (Sigma) was used as
standards, and their positions were visualized by the use of iodine vapors.
RESULTS
Aureobasidin A effect on T. gondii replication. In order to
analyze the sensitivity of T. gondii to the IPC synthase inhibitor
aureobasidin A, we infected HFF monolayers with purified
tachyzoites and subsequently treated them with different con-
centrations of the drug, as described in Materials and Methods.
In untreated cells, parasites completed up to four replication
cycles during the 24 h postinfection, with 60% of vacuoles
containing 8 parasites and 10% containing 16 parasites after
this period (Fig. 2A and B). In contrast, a 10-g/ml aureobasi-
din A treatment severely inhibited parasite replication imme-
diately following infection, with 60% of vacuoles containing
only one parasite and no vacuoles containing more than four
parasites. Moreover, immunofluorescence analysis of intracel-
lular T. gondii treated with aureobasidin A showed the pres-
ence of abnormal parasites with an altered morphology (Fig.
2C).
To analyze whether T. gondii remained sensitive to aureo-
FIG. 1. Sphingolipid synthesis in eukaryotic cells. Schematic repre-
sentation of the synthetic pathways and site of action of the inhibitor
aureobasidin A.
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basidin A or could adapt to the drug after prolonged incuba-
tion, we quantified parasite replication at 48 h postinfection
(Fig. 3A). T. gondii replication was potently inhibited by au-
reobasidin A at 48 h, and this inhibition was dose dependent,
with a 50% inhibitory concentration of 0.3 g/ml. Further-
more, we tested whether the blocking of parasite replication
required the presence of aureobasidin A within the first 24 h of
vacuole formation or whether it also occurred after the estab-
lishment of infection. As shown in Fig. 3B, an aureobasidin A
treatment 24 h after T. gondii infection was still effective at
inhibiting parasite replication, indicating that the initial forma-
tion of the parasite-containing vacuoles was not the crucial step
inhibited by the drug.
To analyze the effect of aureobasidin A on host cell func-
tions, we tested the metabolic activity as a measure of cell
viability. As shown in Fig. 3C, metabolic activities of host cells
were comparable in the absence or presence of aureobasidin A
at 10 g/ml and impaired after cell lysis by a sodium dodecyl
sulfate treatment, indicating that reduced host cell viability was
not responsible for the inhibition of parasite replication.
Reversibility of aureobasidin A inhibitory effect. The revers-
ibility of aureobasidin A inhibition of parasite replication was
tested by removing the drug from T. gondii-infected cells after
24 or 48 h of treatment, followed by a chase in the absence of
the drug. Parasite replication was assessed by counting the
vacuoles containing viable parasites, i.e., vacuoles with at least
eight parasites after 24 h of drug removal (viable vacuoles).
About 60% of the parasites treated with 10 g/ml of aureo-
basidin A for 24 h formed viable vacuoles in the 24 h following
drug removal, suggesting a recovered replication capability.
However, in cells treated for 48 h, viable vacuoles were not
observed even after an additional 48-h incubation in the ab-
sence of the drug (Fig. 4). These results indicate that a pro-
longed exposure to aureobasidin A caused an irreversible in-
hibition of parasite replication.
Analysis of bradyzoite stage conversion during aureobasidin
A treatment. To test whether the treatment with aureobasidin
A arrested parasite replication by inducing tachyzoite to bra-
dyzoite stage conversion instead of causing a lethal effect on
tachyzoites, we performed immunofluorescence analysis with
the bradyzoite-specific antibody BAG5. Intracellular parasites
treated with the drug for up to 6 days did not reveal any
appearance of the BAG5 antigen, whereas infected cells
treated with alkaline medium and ambient CO2 to induce
bradyzoite differentiation showed a positive signal with the
BAG5 antibody, indicating that the arrest in parasite replica-
tion in the presence of aureobasidin A was not accompanied by
stage conversion to the bradyzoite form (Fig. 5).
Aureobasidin A effect on parasite structure. The aberrant
parasite morphology observed in the immunofluorescence
analysis, the irreversibility of the drug-mediated inhibition of
parasite replication, and the lack of bradyzoite stage conver-
sion suggest that the effect of aureobasidin A on T. gondii is
parasiticidal rather than parasitistatic. To further assess the
effect of aureobasidin A treatment on the parasite at the ul-
trastructural level, we performed electron microscopy analysis
of T. gondii-infected HFF treated with 10 g/ml of aureobasi-
din A for 24 h. As shown in Fig. 6, the presence of the drug
FIG. 2. Effect of aureobasidin A on T. gondii replication after 24 h of drug treatment. (A) HFF monolayers were infected for 2 h with T. gondii,
washed to remove extracellular parasites, and subsequently treated with the indicated concentrations of aureobasidin A (AbA). After 24 h of drug
treatment, cells were fixed and permeabilized, and intracellular parasites were quantified by staining with a polyclonal anti-T. gondii tachyzoite
serum, followed by a fluorescein-conjugated secondary antibody. The distributions of the parasite numbers in single vacuoles are expressed as
percentages of the total vacuoles examined (n  30). (B) Immunofluorescence analysis of intracellular parasites treated with vehicle (control) or
10 g/ml of aureobasidin A (AbA) by the use of anti-T. gondii tachyzoite serum (-T. gondii), followed by fluorescein-conjugated secondary
antibodies and DAPI staining. (C) Immunofluorescence analysis of intracellular parasites treated with 10 g/ml of aureobasidin A (AbA) by the
use of anti-T. gondii tachyzoite serum, followed by fluorescein-conjugated secondary antibodies. N, normal parasites; A, aberrant parasites. Bar 
5 m.
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caused severe alterations in the parasite-containing vacuoles,
with an increase in T. gondii vacuolization and a loss of intra-
cellular structures. In addition, the intravacuolar space be-
tween the damaged parasites showed the presence of amor-
phous material, whereas untreated cells showed a more
defined intravacuolar space with a structured membranous tu-
bular network. The morphological analysis suggests the occur-
rence of lysis of parasites and shedding of intracellular material
in the intravacuolar space.
Aureobasidin A effect on sphingolipid biosynthetic path-
ways. Aureobasidin A treatment is lethal to yeast cells by
inhibiting the enzyme IPC synthase and the formation of the
FIG. 3. Effect of aureobasidin A on T. gondii replication after 48 h
of drug treatment. (A) HFF monolayers were infected for 2 h with T.
gondii, washed to remove extracellular parasites, and subsequently
treated with the indicated concentrations of aureobasidin A (AbA).
After 48 h of drug treatment, intracellular parasites were quantified by
a colorimetric assay measuring the amount of parasite-expressed -ga-
lactosidase. Results are presented as percentages of the control (vehi-
cle-treated cells) values  standard errors (n  3). Results of a rep-
resentative experiment (out of three) are shown. (B) HFF monolayers
were infected for 2 h with T. gondii, washed to remove extracellular
parasites, and treated with the indicated concentrations of aureobasi-
din A immediately after infection (AbA day 1) or 24 h postinfection
(AbA day 2). Intracellular parasites were quantified at 48 h postinfec-
tion by a colorimetric assay measuring the parasite-expressed -galac-
tosidase, and data are expressed as described for panel A. (C) Meta-
bolic activity of host cells treated for 48 h with vehicle (control), 10
g/ml of aureobasidin A, or 20% sodium dodecyl sulfate (SDS), as-
sessed by measuring AlamarBlue reduction (Biosource).
FIG. 4. Reversibility of aureobasidin A-mediated inhibition of T.
gondii replication. HFF monolayers were infected for 2 h with T.
gondii, washed to remove extracellular parasites, and treated with 10
g/ml of aureobasidin A for 24 or 48 h, followed by an additional 24-
or 48-h incubation without the drug, respectively. After cell fixation
and permeabilization, intracellular parasites were visualized with an
antiserum against T. gondii tachyzoites followed by fluorescein-conju-
gated secondary antibodies. Parasites were considered viable when
present in at least eight units per vacuole after 24 or 48 h of incubation
in the absence of the drug. Data are expressed as percentages of
vacuoles containing viable or nonviable parasites (total number of
vacuoles examined, 50)  standard errors of a representative from
three experiments done in duplicate.
FIG. 5. Analysis of bradyzoite stage conversion. HFF monolayers
were infected for 2 h with T. gondii, washed to remove extracellular
parasites, and treated either for 6 days with 10 g/ml of aureobasidin
A (AbA) or for 4 days with alkaline medium and ambient CO2 (pH
8.1). After cell fixation in 4% paraformaldehyde and permeabilization
in 0.2% Triton X-100, intracellular parasites were visualized with an
antiserum against T. gondii tachyzoites, followed by fluorescein-conju-
gated secondary antibodies (-T. gondii), or with an antiserum raised
against the bradyzoite-specific antigen BAG5, followed by Cy3-conju-
gated secondary antibodies (-BAG5). Bar  5 m.
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sphingolipid IPC (11). To analyze whether T. gondii contains,
together with the sphingomyelin pathway, a sphingolipid path-
way leading to the formation of IPC which can be inhibited by
aureobasidin A, we radiolabeled the cells with inositol, a pre-
cursor of IPC and phosphatidylinositol (PI). PI and IPC can be
biochemically distinguished by a mild alkaline treatment,
which hydrolyzes only PI (alkaline sensitive) and not IPC (al-
kaline resistant) (12). An analysis of lipids from intracellular T.
gondii incubated with [3H]inositol showed the presence of an
inositol-labeled lipid that was resistant to alkaline treatment
comigrating with alkaline-sensitive PI (Fig. 7A, asterisk). Au-
reobasidin A treatment inhibited the synthesis of this inositol-
labeled lipid, with the concomitant appearance of a slower
migrating band (arrowhead).
In yeast, the aureobasidin A-mediated inhibition of IPC
formation is associated with increased levels of ceramide, the
direct precursor of IPC (7). Therefore, ceramide levels in T.
gondii were tested to assess possible variations in this lipid
concentration due to drug treatment. T. gondii parasites were
labeled with [3H]palmitate, the general precursor of sphingo-
lipids, and the extracted lipids were separated in a suitable
solvent system for resolving ceramide. [3H]palmitate labeling
FIG. 6. Analysis of T. gondii ultrastructure upon aureobasidin A treatment. HFF monolayers were infected for 2 h with T. gondii, washed to
remove extracellular parasites, and treated for 24 h with a vehicle (control) or 10 g/ml of aureobasidin A (AbA). Samples were fixed and
processed for transmission electron microscopy analysis as described in Materials and Methods. Bar  2 m.
FIG. 7. Analysis of sphingolipid synthesis upon aureobasidin A treatment. (A) Representative thin-layer chromatography (TLC) results for
inositol-labeled lipids extracted from T. gondii. HFF monolayers were infected with T. gondii and labeled with myo-[3H]inositol in the presence
of vehicle (control) or 10 g/ml of aureobasidin A (AbA) for 24 h. After washing of the cells, T. gondii tachyzoites were harvested, lipids were
extracted from 108 parasites, and aliquots were processed by mild alkaline hydrolysis (NaOH) and resolved by TLC analysis in solvent system A.
(B) Representative TLC of palmitate-labeled lipids extracted from T. gondii or host cells. Purified parasites (108) or 107 host cells were labeled
with [3H]palmitate in the presence of vehicle (Cntl) or 10 g/ml of aureobasidin A (AbA) for 7 h. Lipids were extracted and resolved by TLC
analysis in solvent system B. Cer, ceramide; SM, sphingomyelin. (C) Densitometric quantification of newly synthesized ceramide versus sphingo-
myelin ratio after labeling with [3H]palmitate. Data are expressed as percentages of newly synthesized ceramide/sphingomyelin in vehicle
(Cntl)-treated parasites or host cells.
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of purified extracellular parasites for 7 h effectively labeled T.
gondii lipids, resulting in a labeling pattern comparable to the
one obtained when parasites were labeled intracellularly for
24 h. In contrast, inositol labeling required a 24-h incubation
time of intracellular parasites, possibly due to a different cell
permeation characteristic of the lipid precursor. Aureobasidin
A treatment increased the ratio of newly synthesized ceramide/
sphingomyelin and concomitantly decreased the total synthesis
of complex sphingolipids in T. gondii. An analysis of newly
synthesized lipids in uninfected host cells did not reveal any
alteration in sphingolipid levels, confirming that aureobasidin
A does not target any sphingolipid biosynthetic enzyme in
mammalian cells (Fig. 7B and C).
DISCUSSION
Sphingolipid synthesis is essential in a variety of fungi, thus
providing an attractive target for antifungal agents (22, 34).
Aureobasidin A, a potent antibiotic which is active against a
variety of pathogenic fungi, has been shown to inhibit IPC
synthase, the enzyme responsible for the synthesis of the sphin-
golipid IPC, which is present in fungi, plants, and some pro-
tozoa but absent from animal cells (21).
In the present work, we showed that aureobasidin A is a
strong inhibitor of T. gondii’s in vitro replication. The inhibi-
tion of parasite replication had occurred already during the
first replication cycles, suggesting that the target of aureobasi-
din A is crucial for the immediate survival of T. gondii inside
host cells.
An analysis of metabolic activity together with direct micro-
scopic observations of host cells treated with aureobasidin A
indicated that the presence of the drug does not cause host cell
cytotoxicity and that the parasite inhibition observed is there-
fore most likely due to a direct effect of aureobasidin A on T.
gondii. Together, these results suggest that aureobasidin A can
be used to prevent T. gondii replication without adverse effects
on host cell biology.
Stage conversion from the rapidly dividing tachyzoite to the
quiescent bradyzoite form is the physiological parasitic re-
sponse to stress conditions, among which are temperature (33),
pH (33, 39), chemical stress (33), and nitric oxide (4). Stage
conversion to the bradyzoite form has also been shown to
occur upon treatment with some agents that are able to reduce
the T. gondii replication rate (37, 38) and was detectable within
3 days of drug treatment. However, T. gondii treated with
aureobasidin A did not show any stage conversion even after 6
days of drug exposure. This observation, together with the
finding that the majority of parasites treated with the drug
could no longer replicate after 48 h of drug treatment and
showed severe damage to intracellular structures, suggests that
aureobasidin A promotes the death of intracellular parasites.
The rapid action of the drug as well as the lethal effect
observed mirrors the effect of aureobasidin A in yeast cells.
Several studies investigating the mechanism of aureobasidin A
action have revealed that the lethality observed in yeast fol-
lowing the inhibition of IPC synthase results from both a de-
crease in the level of the sphingolipid IPC and an increase in
the level of ceramide, the substrate for IPC synthase (7). An
analysis of lipid synthesis in T. gondii revealed the presence of
a lipid that was resistant to alkaline treatment, a known prop-
erty of IPC. In accordance with the effect of aureobasidin A on
yeast IPC, the synthesis of this alkaline-resistant lipid was in-
hibited by aureobasidin A treatment. While these results sup-
port the hypothesis that IPC is present in T. gondii, further
analyses are required to confirm the structure of this lipid and
the presence of an IPC synthetic pathway together with mam-
mal-like pathways in the parasite.
Increases in relative ceramide levels were also monitored in
the presence of aureobasidin A. The drug treatment was shown
to decrease the total synthesis of sphingolipids and to raise the
ceramide/sphingomyelin ratio in T. gondii, indicating that the
lipid synthetic pathway blocked by the drug contains ceramide
as an intermediate step. Ceramide, beside being an interme-
diate element in the biosynthetic pathway of sphingolipids, is
also an important second messenger with a pivotal role in
sphingolipid-mediated signal transduction (23). In yeast, as
well as in mammalian cells, increased levels of ceramide have
been linked to cell cycle arrest and apoptosis (14). Therefore,
the increased relative levels of cellular ceramide observed in T.
gondii could induce cell death and account for the inhibition of
total sphingolipid synthesis observed. Moreover, the inhibition
of alkaline-resistant sphingolipid synthesis, such as that of IPC,
may play an important role in the observed damage to the
parasite’s structure. Indeed, it has been reported that IPC
synthesis is required for the proper organization of filamentous
yeast cells (7). Collectively, these results indicate that the lethal
phenotype observed could have been caused by both the ac-
cumulation of ceramide and/or the lack of a lipid inhibited by
aureobasidin A.
In kinetoplastid parasites, such as Leishmania and Trypano-
soma, IPC is a major component of the sphingolipid pool (25,
29). Interestingly, sphingolipids seem to have different func-
tions in the biology of these parasites. In Leishmania major, de
novo sphingolipid synthesis is necessary in the extracellular
stage for proper trafficking, infectivity, and differentiation to
the intracellular stage of the parasite (9). On the other hand,
sphingolipid synthesis is down-regulated upon differentiation,
indicating that this synthesis is not crucial for survival and
proliferation inside the macrophages of the mammalian host.
Conversely, in the case of Trypanosoma cruzi, production of the
sphingolipid IPC and of glycoinositolphospholipids is up-reg-
ulated during differentiation to the intracellular stage. In T.
cruzi, aureobasidin A treatment at concentrations of 5 to 20
g/ml inhibits the synthesis of both IPC and glycoinositolphos-
pholipids and leads to compromised differentiation and cellu-
lar toxicity (29). Thus, it is clear that in these parasites, sphin-
golipids, particularly IPC, play different yet interconnected
roles which remain partly elusive. However, these studies re-
veal that sphingolipids are likely to have, also in protozoa, both
structural and regulative roles, including membrane modifica-
tion, signal transduction, and vesicular trafficking. In light of
this knowledge and our findings, it would be interesting to
further analyze whether T. gondii also exhibits a stage-specific
regulation of sphingolipid composition during differentiation
into the bradyzoite form as an adaptation mechanism for bra-
dyzoite physiology.
A BLAST search for an IPC synthase in the T. gondii ge-
nome did not reveal IPC synthase candidates. Possible reasons
for the absence of significant homology include species-specific
variations in the enzyme sequence. A comparison of IPC se-
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quences from a variety of fungi, including the human patho-
gens Candida, Cryptococcus, and Aspergillus, revealed that the
C and N termini of the enzyme have little homology among the
different species and that the only conserved regions are the
internal 250 amino acids (17). Therefore, the sequence simi-
larity may be too low to reveal a possible T. gondii IPC synthase
by a homology search.
Aureobasidin A has been shown to be a substrate for the
human MDR1,2 P-glycoproteins (Pgp) (20, 36), which are
members of the ATP-binding cassette (ABC) transporter fam-
ily and mediate the efflux of solutes across cell membranes.
Some Pgp inhibitors, including cyclosporine A and its deriva-
tives, were found to inhibit T. gondii replication, suggesting a
possible role of Pgp in T. gondii physiology (32). In order to
assess a role of Pgp in the inhibition of parasite replication
induced by aureobasidin A, we measured the activity of Pgp in
both host cells and isolated parasites in the presence of aureo-
basidin A and verapamil, a known efficient Pgp modulator.
Both drugs inhibited the efflux of the dye rhodamine 123 in
host cells as well as in extracellular parasites (data not shown),
supporting the presence of an efflux system inhibited by Pgp
modulators in T. gondii (30, 32). However, as no direct corre-
lation between Pgp inhibition and parasite replication was ob-
served, the contribution of a putative Pgp homologue to T.
gondii survival within host cells remains unclear.
In summary, our studies indicate that the replication of T.
gondii is severely and rapidly inhibited by treatment with the
antibiotic aureobasidin A and that such a treatment causes an
inhibition of parasite sphingolipid synthesis without affecting
lipid synthesis and metabolic activity in the host cells. Future
analyses will further characterize the nature of the T. gondii
lipid which is modulated by aureobasidin A treatment and
evaluate the efficacy of aureobasidin A both on T. gondii in-
fection in vivo and on the bradyzoite form of the parasite,
which is responsible for the latent form of infection.
A key factor in developing specific anti-T. gondii treatments
is the identification of essential metabolic pathways that are
restricted to the parasite and absent from mammalian cells,
such as the recently described complete shikimate pathway (5,
28). Our results indicate that the characterization of sphingo-
lipid biosynthetic pathways in T. gondii may lead to the devel-
opment of new compounds specifically targeting sphingolipid
synthesis in the parasite as promising candidates for anti-T.
gondii treatments.
ACKNOWLEDGMENTS
We thank John Boothroyd for kindly providing T. gondii tachyzoites
of the RH strain and Howard Riezman for invaluable advice and
discussions.
This work was supported by grants obtained from Roche Research
Foundation, Novartis Foundation, Swiss National Science Foundation,
and Fondation Pierre Mercier pour la Science, Switzerland.
REFERENCES
1. Aspinall, T. V., D. H. Joynson, E. Guy, J. E. Hyde, and P. F. Sims. 2002. The
molecular basis of sulfonamide resistance in Toxoplasma gondii and impli-
cations for the clinical management of toxoplasmosis. J. Infect. Dis. 185:
1637–1643.
2. Azzouz, N., B. Rauscher, P. Gerold, M. F. Cesbron-Delauw, J. F. Dubremetz,
and R. T. Schwarz. 2002. Evidence for de novo sphingolipid biosynthesis in
Toxoplasma gondii. Int. J. Parasitol. 32:677–684.
3. Bligh, E. G., and W. J. Dyer. 1959. A rapid method of total lipid extraction
and purification. Can. J. Med. Sci. 37:911–917.
4. Bohne, W., J. Heesemann, and U. Gross. 1994. Reduced replication of
Toxoplasma gondii is necessary for induction of bradyzoite-specific antigens:
a possible role for nitric oxide in triggering stage conversion. Infect. Immun.
62:1761–1767.
5. Campbell, S. A., T. A. Richards, E. J. Mui, B. U. Samuel, J. R. Coggins, R.
McLeod, and C. W. Roberts. 2004. A complete shikimate pathway in Toxo-
plasma gondii: an ancient eukaryotic innovation. Int. J. Parasitol. 34:5–13.
6. Carruthers, V. B. 2002. Host cell invasion by the opportunistic pathogen
Toxoplasma gondii. Acta Trop. 81:111–122.
7. Cheng, J., T. S. Park, A. S. Fischl, and X. S. Ye. 2001. Cell cycle progression
and cell polarity require sphingolipid biosynthesis in Aspergillus nidulans.
Mol. Cell. Biol. 21:6198–6209.
8. Dannemann, B. R., D. M. Israelski, G. S. Leoung, T. McGraw, J. Mills, and
J. S. Remington. 1991. Toxoplasma serology, parasitemia and antigenemia in
patients at risk for toxoplasmic encephalitis. AIDS 5:1363–1365.
9. Denny, P. W., D. Goulding, M. A. Ferguson, and D. F. Smith. 2004. Sphin-
golipid-free Leishmania are defective in membrane trafficking, differentia-
tion and infectivity. Mol. Microbiol. 52:313–327.
10. Dubey, J. P. 1998. Advances in the life cycle of Toxoplasma gondii. Int. J.
Parasitol. 28:1019–1024.
11. Endo, M., K. Takesako, I. Kato, and H. Yamaguchi. 1997. Fungicidal action
of aureobasidin A, a cyclic depsipeptide antifungal antibiotic, against Sac-
charomyces cerevisiae. Antimicrob. Agents Chemother. 41:672–676.
12. Fischl, A. S., Y. Liu, A. Browdy, and A. E. Cremesti. 2000. Inositolphosphoryl
ceramide synthase from yeast. Methods Enzymol. 311:123–130.
13. Fuchs, N., S. Sonda, B. Gottstein, and A. Hemphill. 1998. Differential ex-
pression of cell surface- and dense granule-associated Neospora caninum
proteins in tachyzoites and bradyzoites. J. Parasitol. 84:753–758.
14. Hannun, Y. A. 1996. Functions of ceramide in coordinating cellular re-
sponses to stress. Science 274:1855–1859.
15. Hashida-Okado, T., A. Ogawa, M. Endo, R. Yasumoto, K. Takesako, and I.
Kato. 1996. AUR1, a novel gene conferring aureobasidin resistance on
Saccharomyces cerevisiae: a study of defective morphologies in Aur1p-de-
pleted cells. Mol. Gen. Genet. 251:236–244.
16. Hashida-Okado, T., R. Yasumoto, M. Endo, K. Takesako, and I. Kato. 1998.
Isolation and characterization of the aureobasidin A-resistant gene, aur1R,
on Schizosaccharomyces pombe: roles of Aur1p in cell morphogenesis.
Curr. Genet. 33:38–45.
17. Heidler, S. A., and J. A. Radding. 2000. Inositol phosphoryl transferases from
human pathogenic fungi. Biochim. Biophys. Acta 1500:147–152.
18. Hemphill, A., B. Gottstein, and H. Kaufmann. 1996. Adhesion and invasion
of bovine endothelial cells by Neospora caninum. Parasitology 112:183–197.
19. Hemphill, A., and S. L. Croft. 1997. Electron microscopy in parasitology, p.
227–268. In M. Rogan (ed.), Analytical parasitology. Springer-Verlag, Hei-
delberg, Germany.
20. Kino, K., Y. Taguchi, K. Yamada, T. Komano, and K. Ueda. 1996. Aureo-
basidin A, an antifungal cyclic depsipeptide antibiotic, is a substrate for both
human MDR1 and MDR2/P-glycoproteins. FEBS Lett. 399:29–32.
21. Lester, R. L., and R. C. Dickson. 1993. Sphingolipids with inositolphosphate-
containing head groups. Adv. Lipid Res. 26:253–274.
22. Mandala, S. M., R. A. Thornton, J. Milligan, M. Rosenbach, M. Garcia-
Calvo, H. G. Bull, G. Harris, G. K. Abruzzo, A. M. Flattery, C. J. Gill, K.
Bartizal, S. Dreikorn, and M. B. Kurtz. 1998. Rustmicin, a potent antifungal
agent, inhibits sphingolipid synthesis at inositol phosphoceramide synthase.
J. Biol. Chem. 273:14942–14949.
23. Mathias, S., L. A. Pena, and R. N. Kolesnick. 1998. Signal transduction of
stress via ceramide. Biochem. J. 335:465–480.
24. McAllister, M. M., S. F. Parmley, L. M. Weiss, V. J. Welch, and A. M.
McGuire. 1996. An immunohistochemical method for detecting bradyzoite
antigen (BAG5) in Toxoplasma gondii-infected tissues cross-reacts with a
Neospora caninum bradyzoite antigen. J. Parasitol. 82:354–355.
25. McConville, M. J., and A. Bacic. 1989. A family of glycoinositol phospho-
lipids from Leishmania major. Isolation, characterization, and antigenicity.
J. Biol. Chem. 264:757–766.
26. McFadden, D. C., M. Camps, and J. C. Boothroyd. 2001. Resistance as a tool
in the study of old and new drug targets in Toxoplasma. Drug Resist. Updat.
4:79–84.
27. McFadden, D. C., F. Seeber, and J. C. Boothroyd. 1997. Use of Toxoplasma
gondii expressing beta-galactosidase for colorimetric assessment of drug ac-
tivity in vitro. Antimicrob. Agents Chemother. 41:1849–1853.
28. Roberts, F., C. W. Roberts, J. J. Johnson, D. E. Kyle, T. Krell, J. R. Coggins,
G. H. Coombs, W. K. Milhous, S. Tzipori, D. J. Ferguson, D. Chakrabarti,
and R. McLeod. 1998. Evidence for the shikimate pathway in apicomplexan
parasites. Nature 393:801–805.
29. Salto, M. L., L. E. Bertello, M. Vieira, R. Docampo, S. N. Moreno, and R. M.
de Lederkremer. 2003. Formation and remodeling of inositolphosphoceram-
ide during differentiation of Trypanosoma cruzi from trypomastigote to amas-
tigote. Eukaryot. Cell 2:756–768.
30. Sauvage, V., D. Aubert, A. Bonhomme, J. M. Pinon, and J. M. Millot. 2004.
P-glycoprotein inhibitors modulate accumulation and efflux of xenobiotics in
extra and intracellular Toxoplasma gondii. Mol. Biochem. Parasitol. 134:89–
95.
1800 SONDA ET AL. ANTIMICROB. AGENTS CHEMOTHER.
31. Seeber, F., and J. C. Boothroyd. 1996. Escherichia coli beta-galactosidase as
an in vitro and in vivo reporter enzyme and stable transfection marker in the
intracellular protozoan parasite Toxoplasma gondii. Gene 169:39–45.
32. Silverman, J. A., M. L. Hayes, B. J. Luft, and K. A. Joiner. 1997. Charac-
terization of anti-Toxoplasma activity of SDZ 215-918, a cyclosporin deriv-
ative lacking immunosuppressive and peptidyl-prolyl-isomerase-inhibiting
activity: possible role of a P glycoprotein in Toxoplasma physiology. Antimi-
crob. Agents Chemother. 41:1859–1866.
33. Soete, M., D. Camus, and J. F. Dubremetz. 1994. Experimental induction of
bradyzoite-specific antigen expression and cyst formation by the RH strain of
Toxoplasma gondii in vitro. Exp. Parasitol. 78:361–370.
34. Takesako, K., K. Ikai, F. Haruna, M. Endo, K. Shimanaka, E. Sono, T.
Nakamura, I. Kato, and H. Yamaguchi. 1991. Aureobasidins, new antifungal
antibiotics. Taxonomy, fermentation, isolation, and properties. J. Antibiot.
(Tokyo) 44:919–924.
35. Takesako, K., H. Kuroda, T. Inoue, F. Haruna, Y. Yoshikawa, I. Kato, K.
Uchida, T. Hiratani, and H. Yamaguchi. 1993. Biological properties of au-
reobasidin A, a cyclic depsipeptide antifungal antibiotic. J. Antibiot. (Tokyo)
46:1414–1420.
36. Tiberghien, F., T. Kurome, K. Takesako, A. Didier, T. Wenandy, and F. Loor.
2000. Aureobasidins: structure-activity relationships for the inhibition of the
human MDR1 P-glycoprotein ABC-transporter. J. Med. Chem. 43:2547–
2556.
37. Wei, S., F. Marches, B. Daniel, S. Sonda, K. Heidenreich, and T. Curiel.
2002. Pyridinylimidazole p38 mitogen-activated protein kinase inhibitors
block intracellular Toxoplasma gondii replication. Int. J. Parasitol. 32:969–
977.
38. Weiss, L. M., and K. Kim. 2000. The development and biology of bradyzoites
of Toxoplasma gondii. Front. Biosci. 5:D391–D405.
39. Weiss, L. M., D. Laplace, P. M. Takvorian, H. B. Tanowitz, A. Cali, and M.
Wittner. 1995. A cell culture system for study of the development of Toxo-
plasma gondii bradyzoites. J. Eukaryot. Microbiol. 42:150–157.
40. Wong, S. Y., and J. S. Remington. 1993. Biology of Toxoplasma gondii. AIDS
7:299–316.
VOL. 49, 2005 ANTI-TOXOPLASMA GONDII ACTIVITY OF AUREOBASIDIN A 1801
